Survival analysis of 256 patients with oral cancer
10.3969/j.issn.1000-8179.20142030
- VernacularTitle:256例局部晚期口腔癌的生存分析
- Author:
Laiping ZHONG
;
Jian SUN
;
Wei GUO
;
Wenyong TU
;
Hanguang ZHU
;
Tong JI
;
Yongjie HU
;
Jun LI
;
Weimin YE
;
Liqun XU
;
Yue HE
;
Wenjun YANG
;
Yan'an WANG
;
Guoxin REN
;
Qiuming YIN
;
Yili CAI
;
Xi YANG
;
Chenping ZHANG
;
Zhiyuan ZHANG
- Publication Type:Journal Article
- Keywords:
oral cancer;
overall survival;
surgery;
functional reconstruction;
neo-adjuvant chemotherapy;
radiation
- From:
Chinese Journal of Clinical Oncology
2015;46(4):217-221
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To analyze survival in patients with advanced oral cancer from prospective clinical trials. Methods:From 2008 to 2010, 256 patients with oral cancer at clinical stage III/IVA were randomly categorized into two groups. Patients in the experi-mental group received neo-adjuvant chemotherapy, surgery, and post-operative radiation, and patients in the control group underwent surgery and post-operative radiation. All patients were routinely followed-up after treatments. Survival was analyzed using Kaplan–Meier method and log-rank test, and differences were considered statistically significant at P value lower than 0.05. Results: Each group was composed of 128 patients. With the median follow-up period of 60 months, the 5-year overall survival rate was 61.7%and the disease-free survival rate was 53.9%. The overall survival rate (P=0.350) and the disease-free survival rate (P=0.160) were not sig-nificantly different between the experimental and control groups. Patients with positive pathological response to neo-adjuvant chemo-therapy exhibited significantly improved overall survival (P＜0.05). Conclusion:Radical surgery should be emphasized to improve the prognosis of oral cancer. Functional reconstruction could also improve the quality of life and survival of patients. Despite that neo-adju-vant chemotherapy could not improve the survival of patients with advanced oral cancer in entirety, it could benefit patients exhibiting positive treatment responses.
